Not provided
Not provided
Not provided
Not provided
Not provided
No longer viable
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was designed to assess the safety and efficacy of GW813893 in the prophylaxis of VTE following TKR and to provide evidence to enable the selection of the appropriate dose(s) and dose regimen of GW813893 for future investigation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GW813893 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of death OR symptomatic or non-symptomatic blood clots in the legs OR symptomatic blood clots in the lungs within 7 +/- 2 days following total knee replacement surgery. | symptomatic blood clots in the lungs within 7 +/- 2 days following total knee replacement surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of bleeding within 7 +/- 2 days following total knee replacement surgery. | Incidence of bleeding within 7 +/- 2 days following total knee replacement surgery |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials, MD | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Clinical Trials Call Center | Birmingham | Alabama | 35209 | United States | ||
| GSK Clinical Trials Call Center' |
Not provided
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C532873 | 2-(5-chlorothien-2-yl)-N-(1-(1-methyl-2-(morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-yl)ethenesulfonamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Phoenix |
| Arizona |
| 85023 |
| United States |
| GSK Clinical Trials Call Center | Phoenix | Arizona | 85023 | United States |
| GSK Clinical Trials Call Center | Yuba City | California | 95991 | United States |
| GSK Clinical Trials Call Center | St. Petersburg | Florida | 33703 | United States |
| GSK Clinical Trials Call Center | Decatur | Georgia | 30032 | United States |
| GSK Clinical Trials Call Center | Charleston | South Carolina | 29414 | United States |
| GSK Clinical Trials Call Center | San Antonio | Texas | 78217 | United States |